Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

作     者：Florian Hohla Thomas Winder Richard Greil Ferenc G Rick Norman L Block rew V Schally 

作者机构：Ⅲrd Medical Department with Hematology Medical Oncology Hemostasis Rheumatology and Infectious Diseases Oncologic Center Center for Clinical Cancer and Immunology Trials Laboratory of Immunological and Molecular Cancer Research Paracelsus Medical University of Salzburg A-5020 Salzburg Austria Department of Oncology Medical University of Zurich 8091 Zurich Switzerland Endocrine Polypeptide and Cancer Institute Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education Miami FL 33125 United States Department of Urology Florida International University Herbert Wertheim College of Medicine Miami FL 33199 United States Divisions of Hematology/Oncology and Endocrinology Department of Pathology and Department of Medicine Miller School of Medicine University of Miami Miami FL 33136 United States 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第20期

页      面：6102-6112页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Colorectal cancer Targeted treatment Vascular endothelial growth factor Epidermal growth factor receptor Peptide receptors Gastrin-releasing peptide Growth hormone releasing hormone Luteinizing hormone-releasing hormone Cytotoxic analogs 

摘      要：The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.